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Chitosan-Hyaluronate hybrid gel (CHHG) is a self-forming thermo-responsive hydrogel. The current study was undertaken in
order to assess the eﬀect of CHHG on rat’s surgically induced osteoarthritis. Methods. Thirteen rats were included in the study. In
all rats weight-bearing was assessed using a Linton Incapacitance tester. All rats underwent bilateral medial partial meniscectomy.
Four rats received a saline injection in the control knee and a 200-microliter injection of CHHG in the experimental knee. Five
rats received a high-molecular weight hyaluronate injection to the control knee and a 200-microliter injection of CHHG in the
experimental knee. Four rats underwent the same surgical procedure, allowed to recuperate for seven days and then CHHG
and hyaluronate were injected. The animals were followed for 6 weeks. Two weeks after injection of a therapeutic substance the
amount of weight-bearing on each knee was evaluated using a Linton Incapacitance meter. Results. Two weeks after induction
of osteoarthritis there is less pain in the CHHG-treated knee than in the control-treated knee, as determined using a Lintron
Incapacitance meter. After six-weeks the histological appearance of the CHHG-treated knee was superior to that of the controls.
This is indicated by thicker cartilage remaining on the medial femoral condyle as well as less cyst formation in the CHHG-
treated knee. Discussion. CHHG appears to delay progression of osteoarthritis and lessen pain in a rat surgically-induced knee
osteoarthritis model. These results support other published results, indicating that there is an ameliorative eﬀect of chitosan on
human and rabbit osteoarthritis.
1.Introduction
Chitin is a nitrogen containing polysaccharide with mech-
anical strength and stability to chemical degradation. It is
formed in the lower phyla of both the animal kingdom
(Fauna) as the exoskeleton of invertebra like arthropodes, in-
sects,crabs,lobsters,andmollusks,andintheplantkingdom
(Vegetative ﬂora) as well as in fungi. Chitin is probably the
most common polymer found in animals, and can be hydro-
lyzed by a strong alkali to yield chitosan, a substance with
quite diﬀerent properties. Chitosan’s unique features [1, 2]
enable its use in various industries and medical applications.
In contrast to most other biopolymers, chitosan has a
positive electrical charge due to amine groups, both free de-
acetylated and acetylated. This makes it elecrostatically at-
tach to most living tissues that contain negatively charged
surface matrices. Chitosan tends to support tissue healing by
encouraging blood coagulation and allowing attachment of
an endothelial layer on DeBakey-knitted grafts [1, 2]. Appar-
ently the use of chitosan powder or pads allows rapid and
scar free healing in many animal species including cats, dogs,
cows, and zoo animals [3]. The improved healing might be
related to increased permeability of cell membranes and is
dependent on the presence of particles in the proper size [4].2 Advances in Orthopedics
Chitosan in the musculoskeletal system has a compound
eﬀect. Some studies reported diminished bone formation
using chitosan scaﬀold as an interspace in a dog bone-dis-
traction model [5] as compared with calcium phosphate.
Intra-articular injection of chitosan is problematic as it has
been shown to be very inﬂammatory [6]. However, once
again the eﬀect depends on the type of chitosan used. For
example, Liu et al. have reported on the use of 2% car-
boxymethylated chitosan injected intra-articularly as a miti-
gatorofosteoarthritisinarabbitACL-transectionmodel[7],
without observing an inﬂammatory eﬀect, on the contrary
the chitosan appeared to prevent metalloproteinase expres-
sion and protect the articular cartilage from osteoarthritic
damage [7]. Indeed chitosan microspheres have been used
as a slow-release agent for celecoxib injection into arthritic
jointsinrats[8].Theinﬂammatoryeﬀectsofchitosanappear
to be mediated via migration of polymorphonuclear cells
to the particles [9]. The chitosan itself appears to induce
osteopontin expression in white blood cells. Osteopontin is
aninductorofattachmentandspreadofreparativecells[10].
In addition, it appears that chitosan induces collagen type
II and aggrecan gene expression in a rabbit cartilage-injury
model [11].
Thus, while intra-articular chitosan appears to prevent
cartilage destruction and perhaps induce a reparative process
due to cell attachment, it has also been associated with an
inﬂammatory process which appears to be mitigated by
cross-linking of the material and exposure of chitosan to
autologous blood coagulation [12]. The application of chi-
tosan appears to prevent adhesion formation in the rabbit
knee following cartilage damage [13]. The current study has
been performed in order to assess the potential beneﬁcial
eﬀect of an in situ, cross-linked, and self-gelling chitos-
an-HA-hybridformulationontheprogressionofkneeosteo-
arthritis following meniscectomy in rabbits.
2. Methods
2.1. Animal Models and Procedures. Thirteen Wistar rats of
0.3-kilogram-weight male rats were used in the study. The
studywasapprovedbytheAssafHarofeAnimalEthicalCom-
mittee. Knee osteoarthritis occurs predictably after partial
medial meniscectomy [14]. The disease develops in a time-
dependent and predictable fashion. It is a common model
assessing the eﬀect of antiosteoarthritis drugs.
General anesthesia was induced by Ketamine 80mg/kg
and Xylazine 8mg/kg [15]. In the right knee, 200-microliters
of 2% (w/v) chitosan-hyaluronate hybrid gel was injected at
the time of meniscectomy in 9 animals and two weeks after
meniscectomy in another four animals. The contralateral
knee served as control to either saline or hyaluronate (1% gel
200-microliters, produced by Savient Pharmaceuticals, Inc.,
East Brunswick, NJ, USA) was injected.
The rats were allowed unrestricted motion after the sur-
gery and evaluated every six weeks under image intensiﬁ-
cation. The following parameters were evaluated: degree of
medial joint space opening and unloaded joint space width.
After 3 months, the animals were sacriﬁced, and histological
examination was performed.
Animal knees were randomized after incapacitance test-
ing (see below) demonstrated similar weight-bearing on
both hindlimbs. In one knee, either saline (in 4 animals)
or hyaluronate was injected (5 animals). In the contralateral
knee, chitosan-hyaluronate mixture was injected. In another
four animals, the injection was performed under general
anesthesia one week after meniscectomy.
2.2. Chitosan-Hyaluronate Hybrid Gel. A proprietary novel
chitosan-hyaluronic acid hybrid (CHH) from Chi2Gel Ltd.
(http://www.chi2gel.com/)h a sb e e nu s e d .B r i e ﬂ y ,am i x t u r e
of chitosans and oligochitin (FM80, DAC50, and oligochitin
from Koyo chemicals Ltd., Japan) was solubilized in HCl
0.13N and titrated with sodium hydroxide to near pH 7
forming a stable colloidal viscous mixture. This was followed
by an addition of hyaluronic acid (molecular weight of 3
million Dalton, Ferring Ltd.). The resultant solution is a
homogeneous liquid solution at 4◦C that transforms into
a gel at physiological conditions, that is, 37◦C and pH 7.4.
Genipin (Challenge Bioproducts Co., Ltd., Taiwan), a nat-
uralcross-linkerisaddedtotheCHHsolution,at0.2%(w/v)
just before injecting and accelerates the gelation.
2.3. Incapacitance Tester Evaluation. Incapacitance tester is
a device allowing assessing changes in hind paw weight
distribution between the right (osteoarthritic) and left
(contralateral control) limbs. It has been utilized as an index
of joint discomfort and may be useful for the discovery of
novel pharmacologic agents in human OA [16]. The animals
were assessed prior to surgery as well as 24 hours after
surgery for the relative amount of weight bearing on either
knee using a Linton Incapacitance meter (Linton Instrumen-
tation, Norfolk, UK). The animals were ranked according
to the diﬀerence between right limb and left limb weight
bearing. The experimental versus control knees were then
determined so that there was similar distribution of right-
limbed versus left-limbed animals. This step is important
in order to prevent bias related to animal “handedness.”
Animalswereexaminedagaintwoweeksafterinjectionofthe
intra-articular therapy. The animals were examined again 14
days after instillation of the intra-articular therapeutic agent.
2.4. Histological Evaluation. The rats were euthanized using
intraperitoneal 200mg/kg sodium pentobarbital injection.
The knees were dissected out and processed for routine
histology following ﬁxation with 1% cetylpyridinium chlo-
ride—4% formalin solution for 48 hours. Decalciﬁcation
was carried out in EDTA for three weeks on average. Mas-
son’s trichrome and hematoxylin stains were evaluated. The
following parameters were measured: cartilage thickness at
thelowestpartofthemedialfemoralcondyle,osteophytefor-
mation, cyst formation, and subchondral bone plate thick-
ness.
2.5. Statistical Analysis and Image Analysis. Quantitative
histology was performed using an image analysis programAdvances in Orthopedics 3
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Figure 1: (a) rat knees following medial meniscectomy. Cartilage thickness is higher in the chitosan-hyaluronate-hybrid gel-treated knee
than in the hyaluronate-treated knee. (b) environmental scanning electron microscopy seems to indicate that the hybrid gel has an internal
structure. The authors hypothesize that the larger hyaluronate molecules (bright lines) appear to chaperon and organize the smaller chitosan
molecules. (c) subcutaneous injection in rats does not evoke an inﬂammatory response macroscopically. The gel forms a discrete nodule
(arrow head). This contrasts with the often observed intense inﬂammatory reaction previously reported with chitosan injection. The
diﬀerence seems to be related to the method of preparation of the gel and its speciﬁc components. Histologically, the gel nodule (red) is
surrounded by minimal ﬁbrous capsule without inﬂammatory cells aggregation (original magniﬁcation ×10, Safranin red stain).
(ImageJ [17]). Statistical analysis was performed using the
MicrosoftExceladd-inprogramAnalyze-itversion2.22[18].
3. Results
3.1. Animals. All animals survived the surgery, and their
joint did not exhibit any evidence of inﬂammation or wound
breakdown. Weight gain proceeded as expected with the
animals gaining on average 100 grams during the follow-up
period.
3.2. Incapacitance Tester Evaluation. The diﬀerence between
the experimental and control knee averaged 1 ± 2g r a m s
prior to surgery. The relative weight-bearing did not4 Advances in Orthopedics
signiﬁcantly change following meniscectomy (2 ± 2). After
2 weeks, the amount of weight bearing was measured again.
The animals bore weight preferentially on the experimental
knee (16.6 ± 4 grams). This diﬀerence was found to be
signiﬁcantlydiﬀerentfromthatmeasured24hoursfollowing
surgery (Student’s t-test, P<0.017).
3.3. Histological Evaluation. Four parameters were assessed
by a blinded examiner.Cartilage thickness was increased
in the experimental groups (170 ± 8) as compared with
the control knees (108 ± 10) (Figure 1(a)). The diﬀerence
was found to be signiﬁcant (Student’s t-test, P<0.043).
The hybrid gel appears to undergo self-assembly perhaps
due to hyaluronate molecules aligning the smaller chitosan
molecules (Figure 1(b)) and does not seem to induce an
inﬂammatory response when injected subcutaneously in rats
(Figure 1(c)).
Cyst grading was performed using a 4-point scale—0: no
cyst, 1: minimal cyst, 2: large cyst, and 3: very large cyst.
There were no cysts formed in the experimental group
(average grade 0), while in the control group the average
was 0.55 ± 0.5. This diﬀerence was found to be signiﬁcant
(Student’s t-test, P<0.047).
Subchondral bone plate thickness: results showed no sig-
niﬁcant diﬀerence between the groups.
Osteophyte grading was performed using a 4-point
scale—0: no osteophyte, 1: minimal osteophyte, 2: large soft
tissue osteophyte, and 3: large bony osteophyte. Average
gradeinthechitosangroupwas0.8±0.5,whileinthecontrol
group it was 1.2 ±0.3. This diﬀerence was not signiﬁcant.
4. Discussion
Chitosan is a positively charged polymer and is biocompati-
ble, non-toxic, and nonimmunogenic, allowing its use in the
medical,pharmaceutical,cosmetic,andtissuereconstruction
ﬁelds [19]. It has previously been shown to act as a coagu-
lationagentinpenetratinginjuries[20].Theuseofinjectable
chitosan has been limited to date due to its potential to
cause neutrophil recruitment with inﬂammation-like eﬀect
and indeed prevents surgically induced immunosuppression
[21]. Early work on chitosan back to 1999 demonstrated
that intra-articular injection led to cartilage overgrowth and
arthroﬁbrosis [22]. This was possible due to macrophage
reaction observed when chitosan is degraded.
However, in recent years several methods of bypassing
this problem were developed. Injection of mesenchymal cells
embeddedinachitosanmatrixallowsintra-articularsurvival
of the implanted mesenchymal cells, though these cells do
not seem to have participated in cartilage reconstruction
[23]. Indeed the use of intra-articular injection of chitosan
appears to allow adhesion prevention following patellar
fracture ﬁxation (Chinese language article [24]). In addition,
chitosan has been shown to improve joint lubrication
when injected intra-articularly in humans (Chinese language
article [24]). Chitosan has also been used together with a
radioactive agent as a chemical synovectomy agent in hu-
mans [1] in phase I/IIa trials.
The current study demonstrates that the use of chitosan-
HA hybrid injection delays osteoarthritis progression in a
rat meniscectomy model. The injection of chitosan hybrid
appears to be superior to either saline or hyaluronate injec-
tion. The possible mechanisms of action include adherence
to cartilage as described for osteochondral cartilage defects
[12] or a direct cartilage proliferation-enhancing eﬀect as
previouslydescribedbyLuetal.[22].Theresultsofthisstudy
concur with results obtained in previous studies demon-
strating prevention of disc degeneration in rabbits as well as
improved repair of rotator cuﬀ tears in rats using a similar
chitosan hybrid gel [25]. It is possible that the hyaluronate
acts to mitigate the inﬂammatory eﬀect observed when chi-
tosan is degraded, thus explaining the better weight-bearing
and histological features observed in this study.
T h ep r o t e c t i v ee ﬀect apparently leads to reduced knee
pain as determined by increased weight-bearing on the chi-
tosan-hybrid-injected knee as compared with the control
knee.
In summary, it appears that the use of chitosan hybrid
intra-articularly is possible, and that at least in an animal
model it might delay osteoarthritis progression and improve
knee function. Further studies are required to deﬁne the
optimal timing of knee injections as well as the possible of
repeated administration of the therapeutic agent. Further
studies, including a large animal model, are needed in order
to better assess whether such a biomaterial might prove
beneﬁcial in humans.
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